Faron Pharmaceuticals Ltd. and Maruishi Pharmaceutical Co., Ltd. announced today that they have signed a License Agreement which grants Maruishi the exclusive license for the development and commercialization of the Traumakine-program in Japan. This agreement is subsequent to the Letter of Intent which was concluded on December 28th 2010 and the financial details of the agreement were not disclosed.

Download press release